pipeline
ECI is focused on the development of products derived from human plasma and enhanced with chitosan. We look to target conditions such as dry eye disease, burns, chronic wounds, and mucosal membrane dryness.
From liquid eye drops to gels, ointments, specially contoured bandages, and more, our pipeline seeks to transform patient care, improve safety, and help to heal.
Our initial product will focus on treatment for dry eye disease (DED).
eci product pipeline
learn more about:
our products
Our therapeutic formulation is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. We believe this formulation will promote healing of epithelial (surface cell) disorders, such as dry eye disease, ophthalmic burns, and chronic wounds.
patients
Patients who experience conditions ranging from dry eye disease, to diabetic ulcers, and wounds or burns may benefit from our fusion of plasma and chitosan as a forward-thinking and potent strategy to potentially address their conditions with easier access and fewer side effects.
disease states
our platform
Our platform leverages plasma from donated human blood and a proprietary antimicrobial molecule (form of chitosan). The tissue-repairing benefits of plasma-derived products, combined with the sustained action of chitosan, may provide relief and long-lasting therapeutic action.